Алгоритм терапии у больных метастатическим кастрационно-рефрактерным раком предстательной железы: современные подходы и перспективы


Цитировать

Полный текст

Аннотация

Рак предстательной железы (РПЖ) является одной из наиболее актуальных проблем современной онкоурологии. Больныекастрационно-рефрактерным РПЖ (КРРПЖ) представляют собой чрезвычайно гетерогенную группу пациентов, поэтому терапевтический подход должен быть индивидуализирован в каждом конкретном случае. Терапевтические опции могут включать применение гормональной терапии 2-й линии, химиотерапии, вакцинотерапии, использование таргетных препаратов и радиофармпрепаратов. Четких рекомендаций по выбору того или иного препарата в настоящее время не существует. В статье представлен обзор возможных методов терапии у данного тяжелого контингента больных, приведены рекомендации по использованию того или иного препарата в зависимости от ряда прогностических факторов.

Об авторах

Борис Яковлевич Алексеев

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

д-р мед. наук, проф., зам. дир. по науч. работе

Кирилл Михайлович Нюшко

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

канд. мед. наук, вед. науч. сотр. отд-ния онкоурологии

Алексей Сергеевич Калпинский

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

канд. мед. наук, ст. науч. сотр. отд-ния онкоурологии

Андрей Дмитриевич Каприн

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

д-р мед. наук, проф., дир. ФГБУ МНИОИ им. П.А.Герцена

Список литературы

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.
  2. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993; 118: 804-18.
  3. Kantoff P.W, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone - refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
  4. European Association of Urology Guidelines. 2013 ed.; p. 133.
  5. Oh W. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88: 3015-21.
  6. Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: are we making progress in castrate - resistant prostate cancer? Semin Oncol 2013; 40 (3): 361-74.
  7. Manni A, Bartholomew M, Caplan R et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6 (9): 1456-66.
  8. Taylor C.D, Elson P, Trump D.L. Importance of continued testicular suppression in hormone - refractory prostate cancer. J Clin Oncol 1993; 11 (11): 2167-72.
  9. Hussain M, Wolf M, Marshall E et al. Effects of continued androgen - deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone - refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12 (9): 1868-75.
  10. Stein C.A. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26: 3-7.
  11. Fowler J.E Jr, Pandey P, Seaver L.E, Feliz T.P. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448-53.
  12. Kucuk O, Fisher E, Moinpour C.M et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58 (1): 53-8.
  13. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180 (3): 921-7.
  14. European Association of Urology Guidelines. 2014 ed.; p. 155.
  15. Eisenhauer E.A, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (vers. 1.1). Eur J Cancer 2009; 45 (2): 228-47.
  16. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9.
  17. Haapala K, Hyytinen E.R, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1674-51.
  18. Scher H.I, Kelly W.K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone - refractory prostate cancer. J Clin Oncol 1993; 11 (8): 1566-72.
  19. Small E.J, Carroll P.R. Prostate - specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43 (3): 408-10.
  20. Dawson N.A, Mc Leod D.G. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153 (6): 1946-7.
  21. Attard G, Reid A.H, Yap T.A et al. Phase I clinical trial of a selective inhibitor of CYP-17, abiraterone acetate, confirms that castration - resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26 (28): 4563-71.
  22. Attard G, Reid A.H, A’Hern R et al. Selective inhibition of CYP-17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer. J Clin Oncol 2009; 27 (23): 3742-8.
  23. Danila D.C, Morris M.J, de Bono J.S et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxeltreated castration - resistant prostate cancer. J Clin Oncol 2010; 28 (9): 1496-501.
  24. Ryan C.J, Smith M.R, Fong L et al. Phase I clinical trial of the CYP-17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration - resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28 (9): 1481-8.
  25. Reid A.H, Attard G, Danila D.C et al. Significant and sustained antitumor activity in post - docetaxel, castration - resistant prostate cancer with the CYP-17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28 (9): 1489-95.
  26. de Bono J.S, Logothetis C.J, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
  27. Ryan C.J, Smith M.R, de Bono J.S et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (2): 138-48.
  28. Basch E, Autio K, Ryan C.J et al. Abiraterone acetate plus prednisone vs prednisone alone in chemotherapy - naive men with metastatic castration - resistant prostate cancer: patient - reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013; 14 (12): 1193-9.
  29. Tannock I.F, de Wit R, Berry W.R et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-12.
  30. de Bono J.S, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration - resistant prostate cancer progressing after docetaxel treatment: a randomised open - label trial. Lancet 2010; 376 (9747): 1147-54.
  31. Aapro M.S, Bohlius J, Cameron D.A et al. 2010 update of EORTC guidelines for the use of granulocyte - colony stimulating factor to reduce the incidence of chemotherapy - induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47 (1): 8-32; http://10.1016/j.ejca.2010.10.013
  32. Smith T.J, Khatcheressian J, Lyman G.H et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence - based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187-205.
  33. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
  34. Kantoff P.W, Higano C.S, Shore N.D et al. Sipuleucel-T immunotherapy for castration - resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-22.
  35. Scher H.I, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-97.
  36. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213-23.
  37. Smith D.C, Smith M.R, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31 (4): 412-9.
  38. Pili R, Häggman M, Stadler W.M et al. Phase II randomized, double - blind, placebo - controlled study of tasquinimod in men with minimally symptomatic metastatic castrate - resistant prostate cancer. J Clin Oncol 2011; 29 (30): 4022-8.
  39. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
  40. Oudard S et al. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39 (3): 275-89.
  41. van Soest R.J, de Morrée E.S, Shen L et al. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration - resistant prostate cancer treated with docetaxel. TAX327 Study. Eur Urol 2013; http://pii: S0302-2838(13)00828-2
  42. Fizazi K, Flaig Th, Carsten H et al. Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration - resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials. Poster presented at the 2014 Genitourinary Cancers Symposium (ASCO GU). San Francisco 2014, CA.

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах